Exploring Treatment Options for Patients With Renal Cell Carcinoma: Bradley McGregor, MD, and Robert Motzer, MD

In 2021, an estimated 76,080 new cases of kidney cancer will be diagnosed. Among those cases, the majority will be renal cell carcinomas (RCC). In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Expert Guidance on New Advances in Renal Cell Carcinoma, Bradley McGregor, MD, Clinical Director of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, and Robert Motzer, MD, Chair ...

Continue reading

Atezolizumab/Bevacizumab for Advanced Renal Cell Carcinoma: Bradley McGregor, MD, and Toni Choueiri, MD

While metastatic renal cell carcinoma (RCC) has a five-year survival rate of only 10%, patients whose tumors have variant histology or sarcomatoid differentiation face an even more dismal outlook, with limited treatment options. In a study now published in the Journal of Clinical Oncology, a team of researchers led by Bradley McGregor, MD, and Toni Choueiri, MD, reported that atezolizumab in combination with bevacizumab significantly increased progression-free survival and improved outcomes in p...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.